Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

For Occult Cancer in VTE Patients, Routine Screening Is Enough

For the more than 500,000 Americans and Canadians who are diagnosed with unprovoked venous thromboembolism (VTE) each year, VTE may be an early sign...
On location

Study Finds Clinical Benefit for ERY001 in ALL

Asparaginase is a commonly prescribed treatment option for acute lymphocytic leukemia (ALL), but its use can be limited by its toxicities, including drug hypersensitivity....
On location

The DNMT3A R882 Mutation’s Impaired DNA-Damage Sensing: A Key to Overcoming Chemoresistance in AML

A study presented at the 2015 European Hematology Association Congress suggests an important role for DNMT3A R882 mutations in chemoresistance in acute myeloid leukemia...
On location

Early Trials in AML and CMML Offer Promising Results

In early-phase trials conducted in patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), two investigational agents (ASP2215 and CPI-613) and one...
On location

ELOQUENT-2: Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

According to interim results of the phase III, randomized, open-label ELOQUENT-2 study, elotuzumab may offer a new treatment option for patients with relapsed multiple...
On location

Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory CLL

An early-phase study of the combination of venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, with rituximab showed response rates of 80 percent...
On location

Inotuzumab Ozogamicin Improves Complete Remission in Poor-Prognosis ALL

Inotuzumab ozogamicin (InO), an investigational anti-CD22 antibody drug conjugate, demonstrated a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive...
On location

High Response Rates for Brentuximab Vedotin Combinations in HL and DLBLC

High response rates were the hallmark of two clinical trials of brentuximab vedotin (BV) in combination with chemotherapy presented at the 2015 American Society...
On location

Treating the High-Risk APL Patient: ATRA + ATO + GO Might Be the Key

While the combinations of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA+ATO) and of ATRA+ATO plus gemtuzumab ozogamicin (GO; ATRA+ATO+GO) have yielded good clinical...
On location

In Multiple Myeloma, Carfilzomib Bests Bortezomib, But Bortezomib Bests Observation

Two multiple myeloma (MM) studies – one in relapsed disease and the other in newly diagnosed disease after autologous stem cell transplantation (ASCT) –...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.